[Federal Register Volume 85, Number 229 (Friday, November 27, 2020)]
[Notices]
[Pages 76087-76088]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-26169]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The inventions listed below are owned by an agency of the U.S. 
Government and are available for licensing to achieve expeditious 
commercialization of results of federally-funded research and 
development.

FOR FURTHER INFORMATION CONTACT: Licensing information may be obtained 
by communicating with Betty B. Tong, Ph.D., National Institute of 
Diabetes and Digestive and Kidney Diseases, Technology Advancement 
Office, 12A South Drive Suite 3011, Bethesda, MD 20892; telephone: 301-
451-7836; email: <a href="/cdn-cgi/l/email-protection#295d46474e4b694448404507474041074e465f"><span class="__cf_email__" data-cfemail="196d76777e7b597478707537777071377e766f">[email protected]</span></a>. A signed Confidential Disclosure 
Agreement may be required to receive any unpublished information.

SUPPLEMENTARY INFORMATION: Technology description follows.

Triazole Derivatives as P2Y14 Receptor Antagonists

    The technology describes the composition of small molecule 
compounds that are antagonists of the P2Y14 receptor. Also provided are 
methods of using the compounds, including a method of treating a 
disorder, such as inflammation, diabetes, insulin resistance, 
hyperglycemia, a lipid disorder, obesity, a condition associated with 
metabolic syndrome, and asthma, and a method of antagonizing P2Y14 
receptor activity in a cell. This technology is available for licensing 
for commercial development in accordance with 35 U.S.C. 209 and 37 CFR 
part 404.

Potential Commercial Applications:

    Development of P2Y14 receptor antagonist for treatment of 
disorders, such as:
<bullet> Inflammation
<bullet> diabetes
<bullet> obesity
<bullet> asthma

[[Page 76088]]

<bullet> lipid disorder
<bullet> metabolic syndrome

Development Stage

<bullet> Early stage
    Inventors: Kenneth A. Jacobson (NIDDK), Anna Junker, Elisa Uliassi 
(NIDDK), Evgeny Kiselev (NIDDK)
    Publications: Junker A, Balasubramanian R, Ciancetta A, et al., 
Structure-based design of 3-(4-aryl-1H-1,2,3-triazol-1-yl)-biphenyl 
derivatives as P2Y<INF>14</INF> receptor antagonists. J. Med. Chem., 
2016, 59:6149-6168.
    Intellectual Property: HHS Reference No. E-213-2015-0, U.S. Patent 
No. 10,683,277, issued June 16, 2020, EP Patent Application 16774825.0, 
filed Sept. 23, 2016, Chinese Patent Application 201680064441.5, filed 
Sept. 23, 2016.
    Licensing Contact: Betty B. Tong, Ph.D.; 301-451-7836; 
<a href="/cdn-cgi/l/email-protection#44302b2a23260429252d286a2a2d2c6a232b32"><span class="__cf_email__" data-cfemail="cbbfa4a5aca98ba6aaa2a7e5a5a2a3e5aca4bd">[email protected]</span></a>. This notice is made in accordance with 35 U.S.C. 
209 and 37 CFR part 404.

    Dated: November 19, 2020.
Bei Tong,
Senior Licensing and Patenting Manager, National Institute of Diabetes 
and Digestive and Kidney Diseases, Technology Advancement Office.
[FR Doc. 2020-26169 Filed 11-25-20; 8:45 am]
BILLING CODE 4140-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>